AEON Biopharma, Inc. 8-K

What Happened AEON Biopharma, Inc. announced its financial results for the quarter ended March 31, 2026 and furnished a related press release on May 14, 2026. The company filed a Current Report on Form 8-K under Item 2.02 (Results of Operations and Financial Condition) to disclose the quarterly results; the press release is included as Exhibit 99.1 to the filing. The 8-K was signed by Robert Bancroft, President and Chief Executive Officer.

Key Details

• Filing date: May 14, 2026 (Form 8-K, Item 2.02).
• Period covered: Quarter ended March 31, 2026 (Q1 2026 quarterly results).
• Exhibit: Press release dated May 14, 2026 furnished as Exhibit 99.1.
• Signatory: Robert Bancroft, President and CEO, authorized the filing.

Why It Matters This 8-K is the company’s formal disclosure that it has reported its most recent quarterly results (earnings/revenue and related commentary) via a press release. Retail investors should review Exhibit 99.1 (the press release) for the actual financial figures, any commentary on revenue, earnings, cash position, guidance or operational updates that could affect valuation. The Form 8-K itself is a routine but material disclosure mechanism—confirming investors have access to AEON’s published quarterly results and CEO-authorized statements.